Standalone sensitivity at high-sensitivity operating point
92.8 percent
- EndpointFracture detection sensitivity
- PopulationGlobal adult radiograph standalone dataset
- Tested versionBoneView
Concurrent-reading software that highlights suspected fractures on labeled adult radiographs for physician review.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. BoneView adds concurrent fracture highlights within its labeled adult radiograph scope; clinicians still perform the complete image review and clinical assessment.
Evidence takeaway. The FDA submission reports standalone fracture-detection results from 8,918 adult radiographs at two operating points. Those results are limited to the stated endpoint, population, operating point, and BoneView version; they are not reader-aided or site-performance claims.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "Gleamer performed a standalone performance testing on a dataset of 8,918 radiographs" … "of BoneView at the examination-level at the high-sensitivity operating point and high-specificity operating point on the merged datasets High-sensitivity operating point High-specificity operating point Standalone Specificity – 95% Sensitivity – 95% Specificity – 95% Sensitivity". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Packet wording: "Gleamer performed a standalone performance testing on a dataset of 8,918 radiographs" … "of BoneView at the examination-level at the high-sensitivity operating point and high-specificity operating point on the merged datasets High-sensitivity operating point High-specificity operating point Standalone Specificity – 95% Sensitivity – 95% Specificity – 95% Sensitivity". Read from the exact FDA decision document on 2026-11-14.
Previous value withdrawn: The legacy value combines multiple unlabeled numbers and does not identify an endpoint, operating point, population, or tested version. Use the scoped exact-submission evidence metrics instead.
Previous value withdrawn: The legacy value combines multiple unlabeled numbers and does not identify an endpoint, operating point, population, or tested version. Use the scoped exact-submission evidence metrics instead.
92.8 percent
81.1 percent
84.1 percent
93.2 percent
K212365
FDA-reported global operating-point results for the exact BoneView submission.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No exact-product reimbursement determination identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesThis public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: DICOM radiographs of the labeled adult extremity, pelvic, rib, and spine regions.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView
Source context, not route validation: The FDA package describes DICOM source and destination through PACS or an X-ray system, with an intermediate DICOM node, gateway, or API for processing and result return.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView
Source context, not route validation: The FDA package describes on-premises or cloud deployment options; current hosting, security, availability, and local configuration remain unknown.
Scope: Exact FDA submission.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView
Source context, not route validation: Result DICOM images and summary information with annotations or highlighted areas; original images are not altered.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView
Unresolved route: Result DICOM images and summary information with annotations or highlighted areas; original images are not altered.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-04 · FDA 510(k) decision material K212365: BoneView
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K212365.
exact submission · checked 2026-09-04The FDA package describes on-premises or cloud deployment options; current hosting, security, availability, and local configuration remain unknown.
exact submission · checked 2026-09-04The FDA package describes DICOM source and destination through PACS or an X-ray system, with an intermediate DICOM node, gateway, or API for processing and result return.
exact submission · checked 2026-09-04Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K212365.
exact submission · checked 2026-09-04Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.
product family · checked 2026-09-04Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.
exact submission · checked 2026-09-04Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No evidence was promoted. Several records name BoneView, but none identifies the tested build tied to K212365; NCT04532580 says FDA submission but omits the submission number and software version, and other records are pediatric, family-level, or unrelated. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price or commercial contract for the exact submission and version was identified.
No exact-product payer coverage or reimbursement determination was identified in reviewed public material.
Public materials reviewed for this exact submission do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
7 sources - 3 history items
Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Alpha Intelligence Manifolds, Inc.
Authorized purpose: Opportunistic review of frontal lumbar-spine or KUB radiographs in adults aged 50 years and older to flag possible low bone mineral density at L1-L4 for clinician follow-up; a negative result does not rule out low BMD.
AZmed
Authorized purpose: Rayvolve supports clinicians by identifying suspected fractures, joint effusions, and dislocations on labeled radiographic views; it does not replace clinician interpretation.
Velmeni, Inc.
Authorized purpose: Concurrent-read CADe to assist dentists in detecting specified tooth and jaw anatomy, bone-level landmarks, and root-canal-treated teeth in digital radiographs of permanent teeth in patients 15 years or older.
Qure.Ai Technologies
Authorized purpose: qXR-Detect is an adult chest-radiograph concurrent reading aid that identifies, highlights and categorizes suspicious regions of interest across lung, pleura, mediastinum/hila/heart, bone, hardware and other categories; trained clinicians remain responsible for primary interpretation.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history